The moves against the researcher, Thorsten Hagemann, come after investigations by the General Medical Council, akin to a U.S. state medical board, and Hagemann’s former institution, Queen Mary University of London (QMUL), turned up evidence of misconduct. In June, we reported on the retraction of a meeting abstract in The Journal of Pathology and the corrigendum of a Nature paper by Hagemann following the inquiry at QMUL.
A spokesperson from the Medical Practitioners Tribunal Service told the Evening Standard:
The MPTS tribunal has announced its decision [to] erase Dr Hagemann’s name from the medical register.
The MPTS spokesperson added:
It also decided it was necessary to impose an immediate order of suspension to cover the 28 day appeal period.
David Scott, director of science funding at Cancer Research UK, sent us this statement:
Cancer Research UK was informed of an allegation of research fraud involving Professor Hagemann. We take all allegations of scientific misconduct extremely seriously and in line with policy the host university QMUL investigated the allegation. The investigation found evidence of research misconduct and Cancer Research UK terminated funding to Professor Hagemann.
(For those who are interested, Cancer Research UK took a somewhat different approach last year in its dealings with another grantee with problematic images.)
In 2013, Hagemann received £180,000 from the Pancreatic Cancer Research Fund (PCRF) to look to examine
the role of a newly described population of regulatory B cells, which play a central role in suppressing the body’s immune response and have been shown to promote tumour growth in animal models.
The aims of the three-year study were
confirm[ing] the cells’ role in human tumour development, defining the sequence of chemical interactions that regulate their function …
But the PCRF did not ask for a refund their grant, said Maggie Blanks, the charity’s CEO, who said the science was “sound and showed potential.” Subsequently, the PCRF decided to continue the project under the direction of a different researcher at QMUL.
A QMUL spokesperson said:
We are not making further comments pending the publication of the Medical Practitioners Tribunal Service’s written decision when we will review our response.
According to the Evening Standard, Hagemann did not attend his MPTS hearing, and has left the UK.
We can confirm that Thorsten Hagemann is an immunologist and translational expert at Immodulon Therapeutics and that clinical data are managed by third party vendors. Immodulon is aware of the recent issue with the GMC, but it has no bearing on the role that Thorsten carries out at the company.
Another famous case of a doctor being kicked off the medical register is that of Andrew Wakefield, whose now-retracted paper in The Lancet suggested a link between MMR vaccine and autism (which is the second on our list of the ten most highly cited retracted papers).
We were unable to find the current contact details for Hagemann.
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our new daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.